Thiogenesis Therapeutics (TSXV:TTI) Total Tax Payable : C$0.00 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Total Tax Payable?

Thiogenesis Therapeutics's Total Tax Payable for the quarter that ended in Sep. 2024 was C$0.00 Mil.

Thiogenesis Therapeutics Total Tax Payable Historical Data

The historical data trend for Thiogenesis Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Total Tax Payable Chart

Thiogenesis Therapeutics Annual Data

Trend

Dec19

Dec20

Feb21

Feb22

Dec23

Total Tax Payable

Thiogenesis Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Tax Payable	Get a 7-Day Free Trial											-	-	-	-	-

Thiogenesis Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Thiogenesis Therapeutics Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Thiogenesis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

TTIPF:USA Q8M:Germany

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

Executives

Vincent P. Stanton

10% Security Holder